Detalhe da pesquisa
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
2.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496014
3.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
JAMA
; 330(6): 528-536, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552303
4.
Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
Dermatol Ther
; 35(7): e15538, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477952
5.
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Cancer Immunol Immunother
; 70(3): 869-874, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857184
6.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica
; 106(6): 1705-1713, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414850
7.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226764
8.
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Blood
; 132(10): 1022-1026, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925499
9.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood
; 132(20): 2115-2124, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181172
10.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Am J Hematol
; 95(12): 1553-1561, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894785
11.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Oncologist
; 24(7): 955-962, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568021
12.
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Blood
; 129(12): 1646-1657, 2017 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28087540
13.
A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
Kidney Int
; 94(1): 199-205, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29759418
14.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Blood
; 128(18): 2199-2205, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601462
15.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica
; 103(5): 874-879, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419429
16.
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Cytotherapy
; 20(12): 1415-1418, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30385043
17.
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Cancer
; 123(8): 1363-1371, 2017 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27984652
18.
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
Am J Hematol
; 92(9): 879-884, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28512788
19.
Making Progress in PTCL: Significant Unmet Needs.
Oncology (Williston Park)
; 36(5): 296, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576177
20.
Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
Am J Hematol
; 91(7): 672-6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27012928